Christian Gaebler

List of Publications by Citations

51 papers	6,997 citations	30 h-index	64 g-index
64 ext. papers	10,762 ext. citations	28.2 avg, IF	6.18 L-index

#	Paper	IF	Citations
51	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*, **2020**, 584, 437-442	50.4	1167
50	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *ELife*, **2020**, 9,	8.9	784
49	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*, **2021**, 592, 616-622	50.4	730
48	Evolution of antibody immunity to SARS-CoV-2. *Nature*, **2021**, 591, 639-644	50.4	652
47	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell*, **2020**, 182, 828-842.e16	56.2	485
46	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature*, **2012**, 492, 118-22	50.4	401
45	Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. *Cell*, **2013**, 153, 126-38	56.2	376
44	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *New England Journal of Medicine*, **2021**, 384, 2212-2218	59.2	347
43	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *Journal of Experimental Medicine*, **2020**, 217,	16.6	289
42	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*, **2021**, 595, 426-431	50.4	247
41	Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science Translational Medicine*, **2021**, 13,	17.5	178
40	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. *Journal of Experimental Medicine*, **2012**, 209, 1469-79	16.6	131
39	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. *Nature Communications*, **2021**, 12, 4196	17.4	106
38	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. *New England Journal of Medicine*, **2021**,	59.2	93
37	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity*, **2021**, 54, 1853-1868.e7	32.3	83
36	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. *Nature*, **2021**,	50.4	69
35	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature*, **2021**,	50.4	65

34	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals **2020**,		60
33	Persistent cellular immunity to SARS-CoV-2 infection. *Journal of Experimental Medicine*, **2021**, 218,	16.6	59
32	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York **2021**,		54
31	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants **2021**,		54
30	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. *Cell Reports Medicine*, **2020**, 1, 100123	18	46
29	Evolution of Antibody Immunity to SARS-CoV-2 **2021**,		43
28	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. *Nature Medicine*, **2020**, 26, 1339-1350	50.5	43
27	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. *Journal of Experimental Medicine*, **2019**, 216, 2253-2264	16.6	42
26	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses **2020**,		35
25	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. *Journal of Experimental Medicine*, **2020**, 217,	16.6	34
24	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants **2020**,		32
23	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. **2021**,		31
22	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies **2020**,		30
21	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. *Nature Communications*, **2021**, 12, 4886	17.4	30
20	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies **2021**,		27
19	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies **2021**,		24
18	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year **2021**,		19
17	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro **2020**,		15

16	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. *Nature*, **2022**,	50.4	14
15	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. *Journal of Virology*, **2021**, 95,	6.6	11
14	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. *Immunity*, **2022**,	32.3	10
13	Persistent Cellular Immunity to SARS-CoV-2 Infection **2020**,		9
12	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160(BaL.). *Journal of Immunological Methods*, **2013**, 397, 47-54	2.5	8
11	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
10	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7
9	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. *Clinical Chemistry*, **2021**, 67, 1249-1258	5.5	5
8	COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. *Current Opinion in HIV and AIDS*, **2021**, 16, 25-35	4.2	4
7	Engineered extracellular matrix components do not alter the immunomodulatory properties of mesenchymal stromal cells in vitro. *Journal of Tissue Engineering and Regenerative Medicine*, **2013**, 7, 921-4	4.4	3
6	Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. *Journal of Experimental Medicine*, **2021**, 218,	16.6	3
5	Antigen responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir		3
4	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. **2022**,		3
3	TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability **2021**,		2
2	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	1
1	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. **2022**,		1